Jelle Barentsz, MD, PhD

E. David Crawford, MD, Editor-in-Chief of Grand Rounds in Urology, interviews Jelle Barentsz, MD, PhD, Professor of Radiology at the University in Nijmegen in the Netherlands, about prostate cancer suspicions and which metrics define prostate cancer risk. Dr. Barentsz discusses the steps that must be taken if there is a suspicion of prostate cancer and emphasizes the importance that MRIs and molecular markers play in this. He notes that in an optimal world with a perfect MRI a molecular marker test is often unnecessary, but that sometimes we do not have perfect MRIs, and in these cases, molecular marker tests like SelectMDX are good tests to use. However, MRIs offer more information about potential cancer and are also better at excluding more significant cancers than molecular marker tests. Dr. Crawford and Dr. Barentsz come to the conclusion that which is better or necessary often depends on the country the patient resides in.

E. David Crawford, MD, Editor-in-Chief of Grand Rounds in Urology, interviews Jelle Barentsz, MD, PhD, Professor of Radiology at the University in Nijmegen in the Netherlands, about prostate cancer suspicions and which metrics define prostate cancer risk. Dr. Barentsz discusses the steps that must be taken if there is a suspicion of prostate cancer and emphasizes the importance that MRIs and molecular markers play in this. He notes that in an optimal world with a perfect MRI a molecular marker test is often unnecessary, but that sometimes we do not have perfect MRIs, and in these cases, molecular marker tests like SelectMDX are good tests to use. However, MRIs offer more information about potential cancer and are also better at excluding more significant cancers than molecular marker tests. Dr. Crawford and Dr. Barentsz come to the conclusion that which is better or necessary often depends on the country the patient resides in.